These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2494 related articles for article (PubMed ID: 25617986)
1. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499 [TBL] [Abstract][Full Text] [Related]
4. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111 [TBL] [Abstract][Full Text] [Related]
5. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199 [TBL] [Abstract][Full Text] [Related]
6. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503 [TBL] [Abstract][Full Text] [Related]
7. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R; Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790 [TBL] [Abstract][Full Text] [Related]
8. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
9. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185 [TBL] [Abstract][Full Text] [Related]
10. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells. Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551 [TBL] [Abstract][Full Text] [Related]
11. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682 [TBL] [Abstract][Full Text] [Related]
12. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Lin MC Lung Cancer; 2016 Mar; 93():47-54. PubMed ID: 26898614 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745 [TBL] [Abstract][Full Text] [Related]
14. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. Togashi Y; Hayashi H; Okamoto K; Fumita S; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K Lung Cancer; 2015 Apr; 88(1):16-23. PubMed ID: 25704955 [TBL] [Abstract][Full Text] [Related]
15. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448 [TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
17. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581 [TBL] [Abstract][Full Text] [Related]
18. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031 [TBL] [Abstract][Full Text] [Related]
19. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]